Back to search results

Immunological Tolerance for Pre-existing Kidney Transplants

This study is exploring if patients with a well-functioning kidney transplant can stop taking immunosuppression medications. You might be able to join if you are 18 or older and have received a kidney from an HLA-matched living donor between 3 months and 5 years ago, and have not had rejection. The study involves a conditioning treatment with TLI (total lymphoid irradiation) and ATG (rabbit anti-thymocyte globulin), followed by an infusion of hematopoietic stem cells (blood-forming cells) from your original kidney donor. The main goal is to see if you can successfully stop immunosuppression medications after 12 months. The study is currently unclear on its recruitment status and plans to enroll 10 participants.

Study design
This is an interventional study with a planned enrollment of 10 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 12 months, indicating follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05525507

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

Recruiting
PHASE1Ages 18+InterventionalTreatment
University of California, Los Angeles
~10 participants
Updated 2025-11-26 on ClinicalTrials.gov
What's tested:Conditioning and Stem cell infusion

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of successful discontinuation of immunosuppression
Measured over 12 months

Conditions

End Stage Kidney Disease
Immunological Tolerance
Kidney Transplant Failure and Rejection
Chronic Kidney Diseases

Explore related trials

Chronic Kidney Disease, Stage 5Kidney TransplantationHLA Complex

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Jeffrey Veale, MD · PRINCIPAL_INVESTIGATOR · Professor of Urology

Who to contact

Ruth Wynne Jones
[email protected]
424-402-9564
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of successful discontinuation of immunosuppression12 months

    To determine whether patients with pre-existing kidney transplants from a haploidentical living donor can be withdrawn from immunosuppressive drugs while maintaining stable graft function within 12 months of hematopoietic stem cell infusion from the same HLA-identical living donor, preceded by conditioning with TLI and ATG.